S6.14.3 – Louise and Roger React to Empowered SLD Patient Advocates
After the roundtable, Louise Campbell and Roger Green share their reactions to the enthusiastic, empowered advocates who are the Harrison Fellows.
October 9, 2025
After the roundtable, Louise Campbell and Roger Green share their reactions to the enthusiastic, empowered advocates who are the Harrison Fellows.
In this conversation, the organizers of the Stephen A. Harrison Patient Advocacy Fellowship Program discuss their goals for the program.
In this conversation, we learn about how the Stephen A. Harrison Patient Advocacy Fellowship Program started and meet the program organizers and five of the initial Fellows.
Louise Campbell and Roger Green interview Wayne Eskridge and Elena Samsonova of the Fatty Liver Foundation and five of the first class of Harrison fellows about the new Dr. Stephen A. Harrison Patient Advocacy Fellowship program.
Roger Green drives this conversation, which focuses on two issues: impact of US government chaos on the MASH community and how competition might evolve in the in-office scanning market.
Louise Campbell drives this conversation, which focuses largely on issues related to MASH patient management. Her general point is that we need to take a more holistic look at MASH patient management, including self-management. Jörn Schattenberg and Roger Green share comments and questions.
The co-hosts continue their look at major MASH stories from the first half of 2025 and two co-authors from a recent Lancet article on advanced liver screening join Roger Green to discuss their article.
Four leading Key Opinion Leaders join Roger Green to discuss the implications of semaglutide’s approval in the U.S. This conversation covers how the healthcare system will manage the tsunami of new patients resulting from increases in disease education and publicity.
Four leading Key Opinion Leaders join Roger Green to discuss the implications of semaglutide’s approval in the U.S. This conversation covers pharmacotherapy choices and the benefits this decision offers for patients.
Four leading US KOLs join Roger Green to discuss how the recent FDA approval of semaglutide in MASH will lead to dramatic changes in MASLD care in the US.